Premium
Prothrombin times in the presence of edoxaban – in‐vivo experience from King's College hospital
Author(s) -
Patel Jignesh P.,
Chitongo Paradzai B.,
Dighe Preetam,
Roberts Lara N.,
Vadher Bipin,
Patel Raj K.,
Arya Roopen
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15101
Subject(s) - edoxaban , medicine , rivaroxaban , dabigatran , apixaban , intensive care medicine , warfarin , atrial fibrillation
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R.L., Neuberg, D. & Ebert, B.L. (2011) Clinical effect of point mutations in myelodysplastic syndromes. New England Journal of Medicine, 364, 2496–2506. Karoopongse, E., Yeung, C., Byon, J., Ramakrishnan, A., Holman, Z.J., Jiang, P.Y., Yu, Q., Deeg, H.J. & Marcondes, A.M. (2014) The KDM2Blet-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy. PLoS ONE, 9, e107817. Kim, E., Ilagan, J.O., Liang, Y., Daubner, G.M., Lee, S.C., Ramakrishnan, A., Li, Y., Chung, Y.R., Micol, J.B., Murphy, M.E., Cho, H., Kim, M.K., Zebari, A.S., Aumann, S., Park, C.Y., Buonamici, S., Smith, P.G., Deeg, H.J., Lobry, C., Aifantis, I., Modis, Y., Allain, F.H., Halene, S., Bradley, R.K. & Abdel-Wahab, O. (2015) SRSF2 mutations contribute to myelodysplasia by mutantspecific effects on exon recognition. Cancer Cell, 27, 617–630. McGraw, K.L., Nguyen, J., Komrokji, R.S., Sallman, D., Al Ali, N.H., Padron, E., Lancet, J.E., Moscinski, L.C., List, A.F. & Zhang, L. (2016) Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica, 101, e320–e323. Sashida, G., Harada, H., Matsui, H., Oshima, M., Yui, M., Harada, Y., Tanaka, S., MochizukiKashio, M., Wang, C., Saraya, A., Muto, T., Hayashi, Y., Suzuki, K., Nakajima, H., Inaba, T., Koseki, H., Huang, G., Kitamura, T. & Iwama, A. (2014) Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation. Nature Communications, 5, 4177. Steensma, D.P., Bejar, R., Jaiswal, S., Lindsley, R.C., Sekeres, M.A., Hasserjian, R.P. & Ebert, B.L. (2015) Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood, 126, 9–16. Xu, F. & Li, X. (2012) The role of histone methyltransferase EZH2 in myelodysplastic syndromes. Expert Rev Hematol, 5, 177–185.